1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Evoq Remedies Ltd.

Evoq Remedies Ltd.

BBSE:EVOQ
1.86
INR
-0.09
(-4.62%)
63.74MMarket Cap
Evoq Remedies Ltd.
BSE:EVOQ
(Bombay Stock Exchange)

Recent

price

1.86

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
2.39
6.67
100.19
10.77
14.98
2.96
4.72
10.24
- -
Revenue per Share
0.01
- -
7.15
0.7
1.19
0.33
0.04
-0.1
- -
Basic EPS, GAAP
- -
-0.02
0.31
-16.95
-3.2
3.87
-5.98
-0.11
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.02
0.55
17.03
18.22
18.56
17.89
17.79
17.89
Book Value per Share
0.02
0.02
0.55
17.03
18.22
18.56
17.89
17.79
17.89
Tangible Book Value per Share
14
14
1
16
14
14
25
25
25
Basic Weighted Avg Shares
33
91
100
168
204
41
118
255
- -
Sales/Revenue/Turnover
0.5
0.01
9.52
8.72
-18.33
-39.16
-19.45
-5.89
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
- -
Depreciation Expense
- -
- -
7
11
16
5
1
-2
- -
Net Income, GAAP
30.63
40
25
25.17
29.12
26.01
31.2
- -
- -
Effective Tax Rate (%)
0.34
- -
7.14
6.5
7.94
11.16
0.75
-0.94
- -
Profit Margin (%)
- -
- -
7
232
248
252
443
441
443
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
7
232
248
252
445
443
445
Total Equity
- -
1.45
110.72
6.56
-7.84
-3.68
-4.11
- -
- -
Return on Invested Capital (%)
- -
1.15
185.14
6.81
4.93
1.42
0.24
- -
- -
Return on Capital (%)
- -
1.34
186.89
9.13
6.75
1.81
0.25
-0.54
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'24
Sep'25
Mar'25
ST Debt
42
28
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
25
25
Market Capitalization
118
216
64

Working Capital

INR

•

in mil. unless spec.
Mar'24
Sep'25
Mar'25
Total Current Assets
368
475
498
Cash, Cash Equivalents & STI
1
3
2
Accounts Receivable, Net
17
18
86
Inventories
31
16
22
Total Current Liabilities
116
47
55
Payables & Accruals
- -
- -
- -
ST Debt
42
28
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
620.52%
-0.54%
Free Cash Flow
- -
-17,158.59%
-98.11%
Net Income, GAAP
- -
-84.73%
-372%
Sales/Revenue/Turnover
- -
63.17%
116.96%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
41
2025
- -
- -
118
2026
- -
- -
255

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.33
2025
- -
- -
0.04
2026
- -
- -
-0.1

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Evoq Remedies Limited engages in the pharmaceutical business in India, primarily through marketing, trading, distribution, and acting as a commission agent for a wide range of pharmaceutical formulation products, active pharmaceutical ingredients, nutraceuticals, ayurvedic, and herbal products. The company offers approximately 120 products under its own brand name, including antibiotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium supplements, multivitamins, anti-oxidants, and injections; it also trades in sweeteners such as acesulfame potassium, aspartame, and dextrose, amino acids including L-alanine and L-arginine, excipients like bronopol and HPMC, ointments containing adapalene, clobetasol propionate, and clotrimazole, vitamins, sterile products, dairy and spice products, and veterinary feed products, with manufacturing outsourced to third parties. Incorporated in 2010 as Salus Life Science and Research Private Limited, renamed Evoq Remedies Private Limited in 2019, and converted to a public company in 2021, the company is headquartered at A-1106, Empire Business Hub, Science City Road, Ahmedabad, Gujarat, India, and operates primarily in the domestic market. Recent developments include securing a substantial purchase order worth Rs 136 crore from Marlex Pharmaceuticals Inc., receiving INR 192.1 million in funding via private placement in June 2024, approving a public issue of 36 lakh equity shares raising Rs 9.72 crore in March 2022, and appointing Bhumishth Narendrabhai Patel as Managing Director in August 2024, alongside board discussions on preferential share issues and capital increases for growth.